tavi
DESCRIPTION
Review the concept of TAVI Evaluation of patients considered for TAVI Review of evidence Identify future applicationsTRANSCRIPT
![Page 1: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/1.jpg)
TAVI
Dr Vijay Amaranath,DMNIMS,Hyderabad.
![Page 2: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/2.jpg)
Bird’s Eye View
Review the concept of TAVI Evaluation of patients considered for TAVI Review of evidence Identify future applications
![Page 3: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/3.jpg)
Introduction
Rising life expectancy results in an increase of degenerative aortic stenosis
most frequent acquired heart valve disease and if untreated is associated with high mortality.
![Page 4: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/4.jpg)
![Page 5: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/5.jpg)
![Page 6: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/6.jpg)
Operative Mortality for AVRSTS2001
(%)
UKCSR 1999-2001 (%)
EHS 2001
(%)
AVR3.7 3.1 2.7
AVR + CABG 6.3 7 4.3
AVR in octogenarians• 220 pts • Op mortality 13% if AVR• Op mortality 24% if AVR + CABG• Morbidity 60%• Survival 85%, 80%, 73% (1,3,5 yrs)
Benefits of AVR in octogenarians• 81% no/mild disability for daily
activities• 93% feel less disabled• 93% reassured to have access to
treatment despite their age
Eur J Cardio Thorac Surg 2007;31:600-606. Eur J Cardio Thorac Surg 2007;31: 1099-1105. Euro J Cardiothorac Surg 2006; 30: 722-727
![Page 7: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/7.jpg)
Severe AS* - Percent of Patients Treated
J Heart Valve Dis2006;15:312-321; Circulation 2005;J Heart Valve Dis2006;15:312-321; Circulation 2005; European Heart Journal 2003;24:1231-1243;European Heart Journal 2003;24:1231-1243; Heart 1999;82:143-148Heart 1999;82:143-148
Many patients are not surgically treated!
![Page 8: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/8.jpg)
Transcatheter Aortic Valve Implantation (TAVI)
• 1993: Andersen– First description of valve sutured in
stent– Animal model– Encountered major limitations
• Obstruction of coronary ostia
![Page 9: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/9.jpg)
First human implantation: Alain Cribier First human implantation: Alain Cribier April 16, 2002 ( France)April 16, 2002 ( France)
Bovine pericardium valve23mm in diameter
![Page 10: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/10.jpg)
balloon-expandable valves
first generation : Cribier-Edwards valve
Second generation Edwards SAPIEN THV
bovine pericardium that is firmly mounted within a tubular, slotted, stainless steel balloon-expandable stent
![Page 11: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/11.jpg)
![Page 12: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/12.jpg)
‘Sapien’ device • Balloon deployment• Transapical
deployment also• Leaflets in open
mode, more chance for AR
‘Sapien XT’ device • Fewer rows and columns• Shorter stent size• More radial strength grater
durability• More closed form, less
chance for AR
![Page 13: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/13.jpg)
CoreValve Revalving device
first implantation in 2005 - Grube et al• first-generation : bovine pericardial tissue and
was constrained with 25F delivery catheter. • second-generation : porcine pericardial tissue
within a 21 F catheter .
![Page 14: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/14.jpg)
![Page 15: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/15.jpg)
![Page 16: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/16.jpg)
multi-level self-expanding Nitinol frame• upper third - low radial force : sits prosthesis
in the aortic root• middle third - high hoop strength ,valve
leaflets are attached ,avoid impinging the coronaries.
• lower third - high radial force and sits within the left ventricular outflow tract.
![Page 17: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/17.jpg)
![Page 18: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/18.jpg)
Procedure & Hardware
![Page 19: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/19.jpg)
Indications
Logistic EuroSCORE >20% or STS Score > 10.Logistic EuroSCORE >20% or STS Score > 10.
![Page 20: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/20.jpg)
![Page 21: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/21.jpg)
![Page 22: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/22.jpg)
Work upRole of imaging in pre-procedural and post procedural assessment
![Page 23: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/23.jpg)
![Page 24: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/24.jpg)
![Page 25: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/25.jpg)
![Page 26: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/26.jpg)
![Page 27: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/27.jpg)
![Page 28: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/28.jpg)
![Page 29: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/29.jpg)
![Page 30: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/30.jpg)
![Page 31: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/31.jpg)
oversizing relative to the aortic annulus (I)Anchoring to prevent migration(II) sealing to prevent paravalvular aortic regurgitation(III)proper valve functioning to prevent patient-prosthesis mismatch
![Page 32: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/32.jpg)
Patient Evaluation• CT Angiogram
– Arterial calcification– Arterial tortuosity– Minimal luminal diameter
![Page 33: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/33.jpg)
![Page 34: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/34.jpg)
![Page 35: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/35.jpg)
![Page 36: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/36.jpg)
![Page 37: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/37.jpg)
• Vascular access– Sites
• Transfemoral• Transapical
– Left ant. thoracotomy– More direct, shorter catheter– Septal hypertrophy– Ascendra2, Sapien valve
• Transaortic – Upper partial sternotomy– Mini-sternotomy 2/3 RICS– Aorta 5 cm above valve– Less painful, familiar approach– Manipulation of ascending aorta
• Subclavian
Percutaneous or Cut-down technique
Percutaneous or Cut-down technique
![Page 38: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/38.jpg)
Approaches
![Page 39: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/39.jpg)
BAV• Balloon aortic valvuloplasty: 20x30
mm (for # 23) or 23x30 mm (for # 26)
• Appropriate angiographic projection in line with the plane of annulus [LAO200/Cran200]
• midpoint of balloon at the annular level PACE INFLATE CHECK DEFLATE stop pacing
![Page 40: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/40.jpg)
![Page 41: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/41.jpg)
Transfemoral Approach Sapien ValveTransfemoral Approach Sapien Valve
41
RetroFlex 3 introducer Sheath Set
Edwards SAPIEN THV
RetroFlex 3 Delivery System
RetroFlex Balloon Catheter
AtrionInflation Device
RetroFlex Dilator KitCrimper
![Page 42: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/42.jpg)
Hardware
CrimperDilator set Inflation device
![Page 43: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/43.jpg)
Hardware
![Page 44: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/44.jpg)
Transfemoral ApproachValve Deployment
Aortic Pressure
RV pacing: 200/min
![Page 45: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/45.jpg)
Edwards SAPIEN implantation
![Page 46: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/46.jpg)
Edwards SAPIEN implantation
![Page 47: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/47.jpg)
AscendraAscendra™™ Transapical Approach Transapical Approach
47
Edwards SAPIEN™ THV
Ascendra™ Introducer Sheath Set
Ascendra™ Delivery System
Crimper
Atrion Inflation Device
Ascendra™ Valvuloplasy Catheter
![Page 48: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/48.jpg)
Transapical Approach
Direct left ventricular puncture
![Page 49: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/49.jpg)
Transapical Approach
Placement and valve deployment
![Page 50: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/50.jpg)
Transapical Approach
![Page 51: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/51.jpg)
three stages of CoreValve deployment.
![Page 52: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/52.jpg)
transfemoral approach
![Page 53: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/53.jpg)
Subclavian approach
![Page 54: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/54.jpg)
![Page 55: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/55.jpg)
![Page 56: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/56.jpg)
closure device such as Prostar XLTM(Abbott
![Page 57: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/57.jpg)
![Page 58: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/58.jpg)
![Page 59: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/59.jpg)
![Page 60: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/60.jpg)
![Page 61: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/61.jpg)
Occlusive iliac dissection
![Page 62: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/62.jpg)
Iliac artery rupture…
![Page 63: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/63.jpg)
…repaired with a covered stent
![Page 64: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/64.jpg)
lung injury, pneumothorax, or pleural bleeding
respiratory compromise and prolonged
ventilation
cardiac tamponade
Transapical Approach
![Page 65: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/65.jpg)
Complications & Management
Causes of hypotension after TAVI•Vascular complications—iliac rupture
•Ventricular rupture
•Acute valve dysfunction
•Coronary artery obstruction
•Multiple rapid pacing episodes in pts with poor LV function
•‘Suicidal’ LV in severe LVH [After removing AV obstruction LV decompresses to such an extent that the subvalvular hypertrophy obstructs outflow] treated with fluids & avoiding diuretics
•Vascular complications—iliac rupture
•Ventricular rupture
•Acute valve dysfunction
•Coronary artery obstruction
•Multiple rapid pacing episodes in pts with poor LV function
•‘Suicidal’ LV in severe LVH [After removing AV obstruction LV decompresses to such an extent that the subvalvular hypertrophy obstructs outflow] treated with fluids & avoiding diuretics
![Page 66: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/66.jpg)
Coronary obstruction
• Displacing an unusually bulky, calcified native leaflet over a coronary ostium
• height of the coronary ostia, and dimensions of the sinus of Valsalva.
ostia should be minimally located 14 mm away from the leaflets insertion.
![Page 67: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/67.jpg)
Complications & Management
Left main stem compromise with semi-occlusive displacement of calcified nodule from aortic valve.Treated with CPB device explantation AVRAlso PCI/CABG
Left main stem compromise with semi-occlusive displacement of calcified nodule from aortic valve.Treated with CPB device explantation AVRAlso PCI/CABG
![Page 68: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/68.jpg)
(A) Left main coronary artery occlusion resulting from a bulky leaflet displaced over the ostium. (B) Successful percutaneous intervention restored left coronaryflow.
![Page 69: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/69.jpg)
Mitral valve injury
• transvenous, transseptal approach
• antegrade apical approach : avulsion of a mitral chordae
• ventricular end of a transcatheter prosthesis can be expected to contact the anterior mitral curtain
![Page 70: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/70.jpg)
Complications & Management
Significant annular ruptureVentricular perforationSignificant annular ruptureVentricular perforation
•Pericardial drainage, auto-transfusion •Conversion to open surgical closure•Pericardial drainage, auto-transfusion •Conversion to open surgical closure
Device malposition
Device embolization
Device malposition
Device embolization
Overlapping ‘valve in valve’
Urgent endovascular/ surgical management
Overlapping ‘valve in valve’
Urgent endovascular/ surgical management
Major ischemic stroke
Minor ischemic stroke
Hemorrhagic stroke
Major ischemic stroke
Minor ischemic stroke
Hemorrhagic stroke
Catheter-based, mechanical embolic protection
Aspirin, anticoagulants
Anticoagulation reversal, coagulopathy correction
Catheter-based, mechanical embolic protection
Aspirin, anticoagulants
Anticoagulation reversal, coagulopathy correction
![Page 71: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/71.jpg)
Stroke
• atheroembolism • Calcific embolism from the aortic valve• air embolism ; prolonged hypotension, and
dissection of arch vessels
![Page 72: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/72.jpg)
Embolic protection device
![Page 73: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/73.jpg)
Heart block
• Incidence of CHB requiring permanent pacemaker implantation has been higher with the CoreValve (19.2% to 42.5%) than with the Sapien valve (1.8% to 8.5%) [larger profile and extension low into the LVOT
• Occurrence of CHB/LBBB– BAV 46%– Balloon/prosthesis positioning &wire-crossing of the aortic valve 25%– Prosthesis expansion 29%.
• Pre-existing RBBB risk factor for CHB
• Incidence of CHB requiring permanent pacemaker implantation has been higher with the CoreValve (19.2% to 42.5%) than with the Sapien valve (1.8% to 8.5%) [larger profile and extension low into the LVOT
• Occurrence of CHB/LBBB– BAV 46%– Balloon/prosthesis positioning &wire-crossing of the aortic valve 25%– Prosthesis expansion 29%.
• Pre-existing RBBB risk factor for CHB
![Page 74: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/74.jpg)
Complications & Management Aortic Regurgitation
•Typically paravalvular mild or mild-moderate severity•Most of AR disappears or reduces at 1 yr follow-up [13% absent, 80% mild AR]
•Typically paravalvular mild or mild-moderate severity•Most of AR disappears or reduces at 1 yr follow-up [13% absent, 80% mild AR]
![Page 75: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/75.jpg)
Complications & Management
Paravalvular AR
Central valvular AR
Paravalvular AR
Central valvular AR
Post-deployment balloon dilation, rapid RV pacing for stabilization, ‘valve in valve’ implantation
Usually self-limited, Gentle probing of leaflets with a soft wire or catheterDelivery of a 2nd TAVR device, ‘valve in valve’
Post-deployment balloon dilation, rapid RV pacing for stabilization, ‘valve in valve’ implantation
Usually self-limited, Gentle probing of leaflets with a soft wire or catheterDelivery of a 2nd TAVR device, ‘valve in valve’
![Page 76: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/76.jpg)
• Acute renal failure - severe renal dysfunction and dialysis( 3 %) requirement might occur
• Arrhythmia- Atrial fibrillation or ventricular ectopy might be precipitated by cardiac manipulation
![Page 77: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/77.jpg)
Medications post-TAVI
Aspirin for life and clopidogrel for 3 months
patient on anticoagulation Warfarin plus clopidogrel for 1 month post-
TAVI, followed by Warfarin plus Aspirin for 1 year and then continue Warfarin only.
![Page 78: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/78.jpg)
![Page 79: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/79.jpg)
![Page 80: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/80.jpg)
![Page 81: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/81.jpg)
![Page 82: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/82.jpg)
![Page 83: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/83.jpg)
![Page 84: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/84.jpg)
![Page 85: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/85.jpg)
![Page 86: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/86.jpg)
![Page 87: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/87.jpg)
ONGOING TRIALS
![Page 88: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/88.jpg)
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves Trial
Edwards SAPIEN XTTM device and delivery systems: NovaFlex (transfemoral
access) and Ascendra2 (transapical access) in patients with symptomatic, calcific, severe aortic stenosis.
intermediate risk [ STS score of 4-8% ]
![Page 89: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/89.jpg)
SURTAVI
• Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
intermediate risk [ STS score of 3-8% ]
![Page 90: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/90.jpg)
Danish study
Irrespective of risk score randomized to TAVI vs SAVR
![Page 91: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/91.jpg)
TAVI in Degenerated Bioprostheses
• Aortic– Capable with CoreValve and Sapien– Bioprosthesis only– Annular/Size diameter
• CoreValve: not in annulus < 21mm
• Mitral– Transapical approach– Sapien only
• Pulmonary
![Page 92: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/92.jpg)
TAVI in a patient with a history of mitral valve replacement
![Page 93: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/93.jpg)
Valve-in-valve
TAVI in both Stented and stentless bioprosthetic valve dysfunction
![Page 94: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/94.jpg)
newly approved transapical devices
![Page 95: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/95.jpg)
![Page 96: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/96.jpg)
![Page 97: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/97.jpg)
![Page 98: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/98.jpg)
• What is the durability?• What is the role of TAVI in low-gradient AS?• Which institutions should be qualified to perform TAVI?• TAVI for prosthesis degeneration? • Will there be a use of catheter valve implantation in
lower risk population?
![Page 99: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/99.jpg)
TAVI is currently the treatment of choice for patients considered not to be candidates for SAVR and proven alternative in high risk cases .
![Page 100: TAVI](https://reader037.vdocuments.us/reader037/viewer/2022103110/547cdbbbb4af9f4f018b4652/html5/thumbnails/100.jpg)
Thank You